Affymetrix to Start Clinical Trials for CytoScan HD in March, Plans FDA Submission by Midyear | GenomeWeb

By Justin Petrone

Affymetrix will initiate clinical trials for its CytoScan HD cytogenetics array in March, and hopes to submit the assay to the US Food and Drug Administration for clearance by the middle of this year, according to its CEO.

Frank Witney discussed the firm's plans during the JP Morgan Healthcare Conference in San Francisco last week. A company spokesperson this week confirmed the firm's plans but declined to further discuss its dealings with the FDA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.